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Development and Validation of Stability Indicating 
RP HPLC method for the estimation of armodafinil  
and Characterization of its base Degradation Product 
by LC-MS/MS 
Abstract— The present work focuses on the development and 
validation of a rapid, selective and reliable stability indicating 
reverse phase High Performance Liquid Chromatographic 
method for the quantitative analysis of Armodafinil (ARM). 
Armodafinil is a eugeroics drug used for treatment of narcolepsy 
and shift work sleep disorder and also as an adjunctive treatment 
for obstructive sleep apnea. The separation was carried out on a 
Hibar Purospher C18 (250 mm × 4.6 mm; 5µ) column by using 
0.01 M ammonium formate (pH 4.5, Adjusted with acetic acid) 
and methanol as mobile phase in the ratio of 45:55 % v/v. The 
flow rate was maintained at 1 mL/min and the eluents were 
monitored at 220 nm. Stress studies were carried out with 1 
mg/mL of the drug solution, starting with mild conditions and 
followed by intrinsic conditions to achieve sufficient degradation. 
Armodafinil underwent extensive degradation under basic 
hydrolysis condition. The unknown degradation product formed 
(DP I; 6.59±0.2 min) under the basic degradation condition was 
separated on a semi preparative HPLC, characterized by UPLC-
Q-TOF and its fragmentation pathway was proposed. The 
proposed structure of the degradation product was confirmed by 
HRMS analysis. The developed stability indicating LC method 
was validated with respect to accuracy, precision, 
specificity/selectivity and linearity. The degradation product was 
characterized and reported. 
Keywords- Armodafinil; LC-MS/MS; degradation; Validation. 
I. INTRODUCTION
The stress testing of pharmaceuticals has long been 
recognized as an important part in the drug development 
process.  They help in demonstrating the specificity of stability 
indicating methods and to determine the degradation pathways 
and degradation product of the active ingredients. These 
methods are also useful in the investigation of the chemical and 
physical stability of the crystal forms, the stereo chemical 
stability of the drug substances & drug product, mass balance 
issues and for differentiating drug substances related 
degradation products in the formulations. The focus on these 
degradation products are basically due to various health and 
safety considerations. A subset of these impurities may be 
genotoxic in nature posing additional safety concern leading to 
carcinogenicity and genetic mutations. 
Armodafinil (ARM), 2-[(R)-(diphenyl methyl) sulfinyl] 
acetamide, falls under the category of eugeroics. It is used for 
the treatment of narcolepsy and shift work sleep disorder and 
also as an adjunctive treatment for obstructive sleep apnea. [1].  
Few analytical methods are available for the determination 
of ARM in bulk and pharmaceutical dosage form by UV [2] 
and HPLC [3]. Two LC-MS/MS methods were reported for the 
analysis of ARM in human plasma [4, 5]. Jennifer et al have 
reported the chiral analysis of d and l modafinil in human 
plasma and their application to pharmacokinetic studies [6]. 
Enantioselective separation of modafinil was carried out and 
quantified by capillary electrophoresis [7]. Rao et al reported 
an RP-HPLC method for the separation and determination of 
related substances of modafinil [8] and also an enantioselective 
HPLC method for the resolution of synthetic intermediates of 
armodafinil and their related substances [9]. Wei Wang et al 
have reported the enantiomeric separation and determination of 
the enantiomeric impurity of armodafinil by capillary 
electrophoresis with sulfobutyl ether β cyclodextrin as chiral 
selector [10]. Mona Darvish et al had reported a study on a 
possible interaction between quetiapine and armodafinil in 
patients with schizophrenia: An open label multiple dose study 
[11]. Deepti Jain and Pawan K Basniwal had reported the 
intrinsic stability of armodafinil hydrochloride by forced 
degradation and impurity profiling [12]. 
However, this article deals with the development and 
validation of an isocratic RP HPLC method for the 
quantification of ARM in bulk drug, its validation as per ICH 
guidelines [13], semi preparative isolation of the base 
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degradation product formed and to elucidate the degradation 
pathway and plausible structure of the degradation product.  
II. EXPERIMENTAL
A. Instrumentation
A Waters HPLC system equipped with 1515 solvent
delivery system, 2487 dual wavelength absorbance detector 
and a Rheodyne 7725i manual injector with 20µl loop volume 
were used to carry out the stress degradation studies. 
For peak purity and LC/MS studies, a Shimadzu HPLC 
system equipped with LC 20 AD pump, SPD-M20A PDA 
detector, ESI-quadrapole mass spectrometer equipped with an 
SIL-20AC auto sampling units were used. The separation was 
carried out on a Hibar C18 (250 × 4.6 mm, id, 5µm) column. 
The data acquisition and processing were performed using Lab 
Solutions software. LC-MS/MS studies and accurate mass 
measurements were performed using 1290 infinity UHPLC-
quadrapole-time of flight (Q-TOF) mass spectrometer (Agilent 
Technologies, USA) equipped with ESI source with a mass 
range and resolution from 50-3200 amu and 40000 FWHM 
respectively. The data acquisition was performed using 
Analyst® QS software. 
B. Chemicals
Armodafinil was obtained as gift sample from Wockhardt
Pharmaceuticals, Aurangabad, India. HPLC grade methanol 
(Qualigens Fine Chemicals, India) and HPLC water (Milli-Q 
water purification system, France) were used for analysis. 
Analytical reagent grade of ammonium acetate, acetic acid and 
sodium hydroxide were procured from S. D. Fine chemicals 
(Mumbai, India). 
C. High Performance Liquid Chromatography Conditions
The separation of the degradation samples were carried out
on a Hibar C18 column (250 × 4.6 mm, id, 5µm) with a mobile 
phase consisting of Ammonium acetate (0.01M; pH 4.5) and 
methanol in an isocratic elution mode (45:55%V/V) at room 
temperature (16-20˚C). The flow rate was maintained at 1.0 
mL/min. The sample injection volume was 20 µL and eluents 
were monitored at 220 nm. Semi-preparative isolation of 
armodafinil degradation product was carried out with same 
mobile phase on Zorbax C18 (250 × 9.0 mm, id, 5µm) with a 
sample injection volume of 100 µL and the flow rate was 
maintained at 5.0 mL/min. 
D. Mass spectrometry conditions for MS/MS
For MS/MS analysis 10 µL of all the samples were injected
directly into the source by flow injection mode using 
Ammonium acetate (0.01M; pH 4.5) and methanol in the ratio 
of 45:55 %v/v as mobile phase at a flow rate of 0.5 mL/min. 
The mass spectrum was recorded in ESI positive mode. Ultra-
high purity nitrogen and helium were used as curtain and 
collision gas, respectively. The typical ion source conditions 
were: nebulizer gas, 60 psi; dry temperature, 325˚C; dry gas, 
5.0 mL/min; capillary voltage, 5kV; capillary current, 81.787 
nA; vaporizer temperature, 400˚C and dwell time, 200 ms. For 
the collision induced dissociation (CID) experiments, the 
precursor ion was selected using quadrapole analyzer and 
product ions were analyzed by time of flight analyzer. HRMS 
data acquisition was performed by the following source 
conditions: capillary voltage, 5 kV; declustering potential (DP) 
and the collision energy (CE) were -60 V and -10 V, 
respectively; focusing potential, 220 V; resolution 40,000 
(FWHM). 
E. Forced Degradation Study
Forced degradation studies of armodafinil was carried out
under acid, alkaline, oxidative, thermal and photolytic stress 
conditions as per ICH guidelines [14]. A stock solution of 
ARM (1 mg/mL) was prepared by dissolving the appropriate 
amount in a suitable diluent. The stress was induced at a 
concentration of 100 µg/mL; aliquots of samples were 
withdrawn at different time intervals, neutralized to pH 5-7, 
suitably diluted to obtain 10 µg/mL and injected in the 
optimized chromatographic conditions against appropriate 
blank for control and stress conditions. Prior to analysis the 
aliquots of the samples were stored in refrigerator at 4˚C. Prior 
to HPLC and LC-MS/MS analysis, the sample solutions were 
filtered through 0.45 µm membrane filter.  
F. Solution Stability
The primary stock solution of ARM was suitably diluted in
the mobile phase and injected periodically into the column 
against blank to study the stability of the solution. 
G. Preparation of Solutions for Stress Studies
100 mg of the ARM was weighed accurately and
transferred to a 100 mL volumetric flask, a small quantity of 
diluent was added to dissolve the drug and the volume was 
made up with the diluent (Water: Methanol 45:55 %v/v). Stress 
degradation solutions were prepared by diluting 2.5 mL of the 
above solution to 25 mL with HCl (1N),   NaOH (0.1N), water, 
diluent and hydrogen peroxide (6%) respectively for hydrolysis 
and oxidation. Photo degradation of the sample in solid state 
was performed under hot sunlight. 
H. Acid/Base Hydrolysis
Stress solutions of 100 µg/mL were prepared in 1N HCl
and 0.1N NaOH at room temperature and allowed to stand for 
24 hrs. Further to increase the extent of degradation, the 
standard solution (100 µg/mL) prepared in 1N HCl and 0.1N 
NaOH were refluxed at 50° and 60°C for 24 hrs. Samples were 
withdrawn at regular time intervals, neutralized with 10% 
NaOH for acid hydrolysis samples and 10% HCl for base 
hydrolysis samples. They were then diluted ten times with the 
mobile phase prior to analysis with the optimized 
chromatographic conditions.  
I. Degradation in presence of water and diluent
To assess the stability of ARM in the presence of water and
the diluent used for the studies, degradation studies were also 
carried out in the presence of water and the diluent (Water: 
Methanol 45:55 %v/v) used. Stress solutions of 100 µg/mL 
were prepared in water and diluent at room temperature and 
allowed to stand for 24 hrs. Further to increase the extent of 
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degradation, the standard solution (100 µg/mL) prepared in 
water and diluent were refluxed at 50° and 60°C for 24 hrs. 
Samples were withdrawn at regular time intervals, diluted ten 
times with the mobile phase prior to analysis with the 
optimized chromatographic conditions.  
J. Oxidation
Stress solutions of 100 µg/mL were prepared in 6%
hydrogen peroxide at room temperature and allowed to stand 
for 24 hrs. Further to increase the extent of degradation, the 
standard solution (100 µg/mL) prepared in 6% hydrogen 
peroxide were refluxed at 50° and 60°C for 24 hrs. Samples 
were withdrawn at regular time intervals, diluted ten times with 
the mobile phase prior to analysis with the optimized 
chromatographic conditions.  
K. Photo Degradation
For photo degradation studies, a known quantity of ARM
was weighed in a petridish and exposed to hot sunlight for 72 
hrs. The samples withdrawn at regular time intervals were 
diluted ten times with the mobile phase prior to analysis with 
the optimized chromatographic conditions. 
L. Purification of Alkali Degradation Product (PD-I)
The target impurity (DP-I) with retention time of 6.59±0.2
min was separated by isocratic elution mode using Zorbax RP 
C18 (250 × 9.0 mm, id, 5µm) stationary phase and ammonium 
acetate (0.01M; pH 4.5): Methanol (45:55% v/v) as mobile 
phase at a flow rate of 5 mL/min. The eluents were monitored 
at 220 nm and the runtime was 25 min. The isolated compound 
was re-confirmed by chromatographic analysis, the purity of 
DP-I was found to be 99.8% and this sample was used for mass 
analysis (HR – MS/MS). 
III. RESULTS AND DISCUSSION
A. Optimisation of Chromatographic Conditions
Initial separation of ARM was carried out on a Purospher
C18 column (150 × 4.6 mm id, 3µm) and methanol/water as 
mobile phase by varying the organic phase from 80% to 40%. 
ARM was well resolved but with tailing. Hence to obtain a 
symmetric peak the aqueous phase was replaced with buffer. 
Ammonium acetate buffer (0.01M)/Methanol was used at 
different ratios such as 30:70, 40:60, 45:55 and 50:50. Based 
on the retention time, a ratio of 45:55%v/v was optimized to 
achieve retention at about 8.42 ± 0.2 min.  In order to obtain 
better theoretical plates, trials were performed by varying the 
pH of the aqueous phase from 2.5 to 4.5. A pH of 4.5 was 
optimized for the analysis. 
Hence a better resolution between the ARM and 
degradation products was achieved with Hibar purospher C18 
(250 × 4.6 mm id, 5µm) column as stationary phase and 
ammonium acetate (0.01M, pH 4.5 adjusted with acetic 
acid)/methanol (45:55% v/v) as mobile phase in isocratic 
elution mode. The flow rate was maintained at 1 mL/min, the 
injection volume was 20 µL and the eluents were monitored at 
220 nm with 20 min as runtime for each analysis. The 
chromatogram of the standard ARM (10 µg/mL) is shown in 
Fig: 1. The method showed good separation between the 
degradation products formed during the degradation studies 
under various degradation conditions and ARM. The retention 
time of the major degradation product formed in acid and base 
degradation study was 6.59 ± 0.2 min (DP-I). The resolution 
among DP-I, DP-II and ARM was significant and was found to 
be more than 2.  The results were tabulated in table-1. For LC-
MS/MS and HRMS studies, the same method was used as 
HPLC, without the replacement of buffer.  
B. Validation
The developed method was validated as per ICH (Q2)
guidelines with respect to selectivity, specificity, linearity, 
accuracy, precision, robustness, limit of detection (LOD)/Limit 
of Quantification (LOQ). [13]. 
 Specificity: The samples of forced degradation studies
were used to demonstrate the specificity and selectivity
of the developed stability indicating analytical method.
The study employed the samples generated during the
degradation of ARM during photo degradation
(exposure to sunlight, 72 hrs), Hydrolysis (1M HCl - at
room temperature, Reflux at 50° and 60°C for 24 hrs,
0.1M NaOH - room temperature, Reflux at 50° and
60°C for 24 hrs,  Water - at room temperature, Reflux
at 50° and 60°C for 24 hrs, Diluent - at room
temperature, Reflux at 50° and 60°C for 24 hrs) and
oxidation (6% Hydrogen peroxide, at room
temperature, Reflux at 50° and 60°C for 24 hrs). The
degradants formed were adequately separated and well
resolved from ARM, thus demonstrating the specificity
and selectivity of the developed stability indicating
analytical method. The peak purity was found to be
greater than 99%.
 Linearity and Range: The linearity of the developed
method for ARM was studied in the range of 0.5–35
µg/mL at nine different concentrations. Samples were
analyzed in triplicate at nine concentrations. The linear
regression equation and correlation coefficient were Y
= 64717x + 901 and 0.9987 respectively demonstrating
the linearity of the method. The results are tabulated in
table-2.
 Accuracy: The accuracy of the method was measured
in terms of recovery studies using standard addition
method at 80, 100 and 120% levels of the sample
concentration. The results were carried out in triplicate
and the recoveries of the drug was calculated from the
difference in peak areas of the fortified and unfortified
samples. Excellent recoveries were observed between
98-102%. (Table-2)
 Precision: The intra and inter day precision was
assessed using three quality control samples in the
linearity range. Six replicates were analysed to
determine the intraday precision. The inter day
precision of the method was determined by repeating
the procedure six times over three days.  The % RSD
values for the intra and inter day precision studies were
<2%, indicating that the developed analytical method
is precise. (Table-2)
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 Limit of detection and Limit of Quantification: The
sensitivity of the analytical method was expressed in
terms of LOD and LOQ which represent the
concentration of analyte that would yield a signal to
noise ratio of 3 for LOD and 10 for LOQ. The LOD
and LOQ were found to be 0.1 and 0.3 µg/mL
respectively. This was confirmed by preparing and
analyzing these predicted concentrations in triplicate
with the optimized chromatographic conditions.
(Table-2)
 Robustness & Ruggedness: The robustness of the
method was determined by making small but deliberate
changes in the method parameters such as change in
flow rate (± 0.2 mL) and pH ((± 0.1 units). The
resolutions between the closely eluting peaks were
greater than 2 demonstrating that the method is robust.
The ruggedness of the method was checked by
different analyst on different instruments (Shimadzu
and Agilent HPLC). The critical parameters were
assessed and found to be within the limits indicating
the ruggedness of the developed analytical method.
C. Forced degradation studies
 Acid induced Degradation: ARM on treatment
with 1N HCl at room temperature for 24hrs
showed 6.20% degradation. To enhance the rate of
degradation ARM on treatment with 1N HCl was
refluxed for 24 hrs at 50° and 60°C, which showed
13.82 and 34.33% degradation. One degradant
(DP I) was observed at the Rt of 6.49 min under
all the conditions. The area % of the degradant
was 1.59, 1.70 and 2.63 respectively when
exposed to 1N HCl at RT (room temperature),
reflux at 50° and 60°C for 24 hrs respectively. The
assay % of ARM after 24 hrs in 1N HCl at RT,
reflux at 50° and 60°C was 98.32%, 99.28 % and
75.44% respectively (Table-3). The chromatogram
of acid induced degradation at room temperature is
shown in Fig. 2.
 Base induced Degradation: When ARM was
subjected to basic degradation with 0.1N NaOH at
room temperature showed 99.91% degradation.
Also ARM was subjected to intrinsic degradation
by refluxing at 50° and 60°C for 24 hrs. One
degradant (DP I) eluted at Rt of 6.42 min when the
sample was subjected to base hydrolysis at room
temperature for 24 hrs. Whereas under reflux
conditions the drug completely degraded with the
formation of two degradation products at the
retention times of 6.42 min and 9.34 min. The area
% of the degradant DP I was 99.89% and assay %
of ARM was 0.11% at room temperature. Under
intrinsic conditions (reflux at 50° and 60°C for 24
hrs) the area % of degradants DP I and DP II, were
found to be 98.49, 0.58% and 97.66, 2.63% 
respectively at 50° and 60°C. Also the assay % of 
ARM was found to be 0.11 and 0.014% during 
reflux at 50° and 60°C for 24 hrs   (Table-3). The 
chromatogram of base induced degradation is 
shown in Fig. 3. 
 Degradation in presence of water and diluent:
When ARM was treated with water and diluent
(Methanol: water, 55:45%w/w) for 24 hrs at room
temperature, no degradation was observed. Further
the samples were also studied under intrinsic
conditions of refluxing with water and diluent at
50° and 60°C for 24 hrs. No degradation products
were observed under intrinsic conditions. With
water the assay % of ARM was found to be 99.03,
98.22 and 96.97% respectively at room
temperature, reflux at 50° and 60°C for 24 hrs.
Whereas with the diluent assay % of ARM was
found to be 99.72, 96.88 and 94.63% respectively
at room temperature, reflux at 50° and 60°C for 24
hrs (Table-3). The chromatograms of the water
and solvent induced degradation are shown in Fig.
4, 5.
 Oxidative degradation: When ARM was treated
with 6% H2O2 for 24 hrs at room temperature,
only 5% of degradation was observed and the
assay of ARM was found to be 96.32%. To
enhance the rate of degradation ARM was treated
with 6% H2O2 and was refluxed at 50° and 60°C
for 24 hrs. No degradation products were observed
and the assay % of ARM was found to be 94.97
and 94.11% respectively when refluxed at 50° and
60°C for 24 hrs   (Table-3). The chromatograms of
the oxidative degradation are shown in Fig. 6.
 Photo degradation: When ARM was exposed to
hot sunlight for 72 hrs (hot sunny light equivalent
to 18 times of 1.2 million lux hrs) 11.56% of
degradation was observed with the formation of
one degradation product at Rt of 6.79 min. The
area % of the degradant (DP I) was 0.07 % and the
% assay of ARM was found to be 99.93% (Table-
3). The chromatograms of photo degradation are
shown in Fig. 7.
D. Degradation behavior of Armodafinil
From the degradation studies carried out under
acid/base/neutral hydrolysis, oxidation and photolytic 
conditions, it was observed that the drug undergoes extensive 
degradation under base hydrolysis. Only one degradation 
product (DP-I) was formed under acid hydrolysis and 
photolytic conditions. But under intrinsic conditions of base 
hydrolysis two degradation products were observed (DP-I, DP-
II). The retention of DP-I was 6.59 ± 0.2 min and DP-II was 
found to be 9.34 ± 0.2 min. Since the % of degradation under 
base hydrolysis was about 99%, the DP-I was isolated from the 
base hydrolysis samples by subjecting them to semi preparative 
HPLC conditions. The chromatographic and system suitability 
parameters such as Rt, RRT, peak purity, resolution, tailing 
factor, theoretical plates and asymmetry factor for ARM and 
DP-II are reported in Table-1. 
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E. Characterization studies by LC-MS/MS studies
The isolated target impurity (DP-I) was subjected to LC-
MS/MS analysis. (Fig.8) 
The hydrolysis of ARM under basic condition yielded two 
degradation products (DP-I, DP-II) in the presence of 0.1N 
NaOH at room temperature for 24 hrs. Since DP-I was the 
major degradation product, it was further isolated for chemical 
characterization. The molecular ion peak of DP-I appeared at 
an m/z of 261 (M+3H). The formation of this ion may be due 
to the hydrolysis of the amide moiety (release of Ammonia) 
leading to the formation of aromatic aldehyde. The major MSn 
fragment ions of DP-I were observed at m/z 218 and 169. The 
m/z at 218 [M+2H; 2-((diphenyl methyl) hydroxyl) sulfonium 
ion] may be formed due to the loss of –CH2CHO ion from m/z 
261. Further elimination of the sulphonyl group may lead to the
formation of the base peak at m/z 169 [M+2H; di phenyl
methylium ion]. Based on the MSn fragmentation studies DP-I
and the formation of base peak at m/z 169, the DP-I was
further identified as 2-(benzhydryl sulpinyl) aldehyde which is
also supported by the literature [12]. The plausible structure of
DP-I, and the fragmentation pathway are shown in Fig. 9.
TABLE I. SYSTEM SUITABILITY PARAMETERS OF ARMODAFINIL AND ITS 
DEGRADATION PRODUCT DP-I 
comp
ound 
System suitability parameters 
Rt 
(min) 
RRT PPI Rs Tf As N 
DP-I 
6.59
±0.2 
0 0.99 0 0.98 1.05 13966 
ARM
8.41
±0.2 
1.28 0.99 2.25 0.97 0.96 14238 
TABLE II. VALIDATION SUMMARY 
Validation summary 
Accuracy (% Mean Recovery ± SD; %RSD) 
Concentration spiked level 1x  99.76±0.45; 0.58 
Concentration spiked level 2x  99.88±0.75; 0.67 
Concentration spiked level 3x  99.02±0.64; 0.54 
Linearity 
Linearity range       0.5-35 µg/ml 
Slope       64717 
Intercept      901 
Correlation coefficient   0.9987 
Precision 
Intraday precision (% Mean Recovery ± SD; %RSD) 
Concentration spiked level 1y       10.05±0.03; 0.31 
Concentration spiked level 2y       19.93±0.20; 1.02 
Concentration spiked level 3y       29.98±0.19; 0.62 
Interday precision (% Mean Recovery ± SD; %RSD) 
Concentration spiked level 1y       10.04±0.05; 0.49 
Concentration spiked level 2y       19.97±0.36; 1.82 
Concentration spiked level 3y       29.96±0.19; 1.37 
Sensitivity 
Limit of Detection       0.100 µg/ml 
Limit of Quantification    0.300 µg/ml 
concentration –level 1 = 10 µg/ml; concentration –level 2 = 20 µg/ml; concentration –level 3 = 30 
µg/ml; x Average of three determinations; y Average of six determinations 
TABLE III. DEGRADATION DATA OF ARMODAFINIL 
Stress 
condition 
Degradation data of Armodafinil 
No of 
degradants 
Retention 
time (min) 
% 
Degradation 
at tR 
% 
Assay 
of ARM 
1N HCl (RT, 
24 hrs) 
1 DP-I: 6.49 1.59 98.32 
1N HCl 
(50°C, 24 
hrs) 
1 DP-I: 6.49 1.70 99.28 
1N HCl 
(60°C, 24 
hrs) 
1 DP-I: 6.82 2.63 75.44 
0.1N NaOH 
(RT, 24 hrs) 
1 DP-I: 6.42 88.16 
9.52 
0.1N NaOH 
(50°C, 24 
hrs) 
2 
DP-I: 6.42 
DP-II: 9.34 
98.49 
0.58 
0.11 
0.1N NaOH 
(60°C, 24 
hrs) 
2 
DP-I: 6.42 
DP-II: 9.33 
97.66 
2.63 
0.014 
Water (RT, 
24 hrs) 
- - - 99.03 
Water (50°C,  
24 hrs) 
- - - 98.22 
Water (60°C, 
24 hrs) 
- - - 96.97 
Diluent (RT, 
24 hrs) 
- - - 99.7 
Diluent 
(50°C,24 
hrs) 
- - - 96.88  
Diluent 
(60°C,24 
hrs) 
- - - 94.63 
6% H2O2 
(RT, 24 hrs) 
- - - 98.43 
6% H2O2 
(50°C,24 
hrs) 
- - - 94.97 
6% H2O2 
(60°C,24 
hrs) 
- - - 94.11 
Sunlight (72 
hrs) 
1 6.71 0.63 97.36 
TABLE IV. ELEMENTAL COMPOSITION OF DP-I IN MS/MS SPECTRRA 
Analyte 
Elemental composition of DP-I in MS/MS spectra 
Observed 
ion mass 
Proposed 
formula 
Calculated 
mass 
DP-I 
261.1044 C15H14O2S 261.0949 
218.1887 C13H12OS 218.0765 
169.9697 C13H12 170.1096 
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Fig 1: Typical Chromatogram of standard Armodafinil 
Fig 2: Chromatogram of Acid degradation sample with 1N HCl at room 
temperature after 24 hrs 
Fig 3: Chromatogram of base degradation sample with 0.1N NaOH at room 
temperature after 24 hrs 
Fig 4: Chromatogram of neutral degradation sample with water at room 
temperature after 24 hrs 
Fig 5: Chromatogram of neutral degradation sample with diluent at room 
temperature after 24 hrs 
Fig 6: Chromatogram of oxidative degradation sample with 6% H2O2 at room 
temperature after 24 hrs 
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Fig 7: Chromatogram of oxidative degradation sample with 6% H2O2 at room 
temperature after 24 hrs 
Fig 6: MSn spectra of the base degradation product DP-I 
Fig 8: MSn spectra of DP-I 
Fig 9: Plausible degradation pathway of base degradation product DP-I 
IV. CONCLUSION 
A simple, sensitive and specific stability indicating RP 
HPLC method was developed for the analysis of ARM in bulk 
drug and validated as per ICH guidelines. One degradation 
product was formed during the base degradation studies and it 
was well resolved from the API by the proposed LC method. 
The proposed structure of the base degradation product was 
characterized by MSn studies and further confirmed by HR-MS 
data and accurate mass measurements. 
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